610798-31-7

Basic information

• Product Name: Icotinib
• Synonyms: BP-1096;BPI-2009H;ConMana;Lcotinib;Icotinib;N-(3-Ethynylphenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododecino[2,3-g]quinazolin-4-amine;BPI-2009;[1,4,7,10]Tetraoxacyclododecino[2,3-g]quinazolin-4-amine, N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-
• CAS NO: 610798-31-7
• Molecular Formula: C22H21N3O4
• Molecular Weight: 391.43
• EINECS: 1592732-453-0
• Product Categories: API;Inhibitors
• Mol File: 610798-31-7.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 581℃
• Flash Point: 305℃
• Appearance: /
• Density: 1.31
• Solubility: insoluble in H2O; ≥129.6 mg/mL in DMSO; ≥14.13 mg/mL in EtOH with ultrasonic
• PKA: 5.32±0.20(Predicted)
• CAS DataBase Reference: Icotinib(CAS DataBase Reference)
• NIST Chemistry Reference: Icotinib(610798-31-7)
• EPA Substance Registry System: Icotinib(610798-31-7)

Safety Data

• Hazardous Substances Data: 610798-31-7(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 610798-31-7 differently. You can refer to the following data:
1. Icotinib is a highly selective, 1st generation EGFR-TKI (epidermal growth factor receptor tyrosine kinase) inhibitor. The mutations of EGFR is associated with many kinds of cancers. Currently, Icotinib is under investigation for its treatment efficacy on some cancer such as non-small cell lung cancer. Icotinib take effects through binding reversibly to the ATP binding site of the EGFR protein, further preventing completion of the signal transduction cascade.
2. Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with IC50 of 5 nM.

Description

Icotinib is also known as ConMana. It is a highly selective, first-generation inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TKI), whose mutation and overexpression is involved in many kinds of cancer. Icotinib is a quinazoline derivative that binds reversibly to the ATP binding site of the EGFR protein, being capable of blocking the signal transduction cascade. It is currently under investigation for its treatment efficacy on the EGFR+ Non-small cell lung cancer.

Indications

Icotinib (Conmana?, BetaPharma), an EGFR inhibitor, was approved by the China State FDA in 2011 for the treatment of NSCLC. Icotinib resembles erlotinib in possessing the N-(3-ethylnylphenyl) quinazolin-4-amine core scaffold of erlotinib that binds to the EGFR ATP pocket. An adjacent hydrophobic group was also retained while the solvent exposed two 2-methoxyethyoxysubstituents at the 6- and 7-positions of the quinazoline core were cyclized to afford the tetraoxacyclododecene moiety of icotinib. Efficacy and safety of icotinib as first-line therapy in patients has been evaluated for advanced NSCLC in recent clinical studies.

References

Tan, F., et al. "Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. " Lung Cancer76.2(2012):177-82. Shi, Y., et al. "Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial." Lancet Oncology 14.10(2013):953-61. Sun, Y., Y. Shi, and L. Zhang. "A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN)."Journal of Thoracic Oncology 29.15(2011):-. https://en.wikipedia.org/wiki/Icotinib

Upstream product

• 938185-06-9 N-(3-ethynylphenyl)-6,7-dihydroxy-4-quinazolinamine 
• 1204313-58-5 4-chloro-7,8,10,11,13,14-hexahydro-6,9,12,15-tetraoxa-1,3-diaza-cyclododeca[b]naphthalene 
• 54060-30-9 3-acetylenephenylamine 
• 1204313-57-4 C₁₄H₁₆N₂O₅ 
• 1403772-39-3 C₁₄H₁₉NO₆ 
• 2150-43-8 3,4-dihydroxybenzoic acid methyl ester 
• 1403772-23-5 C₁₄H₁₇NO₈ 
• 1066-54-2 trimethylsilylacetylene 
• 180475-66-5 ethyl 3,4-(benzo-12-crown-4)benzoate 
• 83506-93-8 2-amino-4,5-difluorobenzoic acid 
• 205259-37-6 6,7-difluoro-3,4-dihydroquinazolin-4-one 
• 211374-80-0 2-amino-4,5-difluorobenzamide 
• 112-27-6 2,2'-[1,2-ethanediylbis(oxy)]bisethanol 
• 1204313-51-8 Icotinib hydrochloride 

Relevant articles and documents

Design, synthesis and antitumor activity of icotinib derivatives

EGFR-TK pathway is of high importance for the treatment of non-small-cell lung cancers (NSCLC), and it will be challenging to develop anti-tumor drugs that could inhibit both EGFR wild-type and mutant tumor cells. Here, a series of icotinib derivatives containing 1,2,3-triazole moiety were designed and synthesized through copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) reactions. Preliminary CCK-8 assay showed that the prepared icotinib-1,2,3-triazole compounds such as a7 or a12 demonstrated potent in vitro antitumor activity against the NSCLC cells expressing both wild type EGFR and mutational EGFR. Further, the mechanism of action for compounds a7 and a12 induced NSCLC cells death was also detailed, and the results suggested a possible induced NSCLC cells death via inducing mitochondrial apoptosis and arresting cell cycle. Remarkably, the inhibition of EGFR by these icotinib derivatives was also studied. The results showed that compound a12 was a potent inhibitor for EGFR with IC50 value of 1.49 μM. Combining these results, an EGFR inhibitor a12 represents a promising new anti-NSCLC candidate that could induce apoptosis and arrest cell cycle.

Quinolinamine compound with IDO1 inhibition function and preparation method thereof

The invention discloses a quinolinamine compound with an IDO1 inhibition function and a preparation method of the quinolinamine compound, and belongs to the technical field of medicine synthesis. According to the technical scheme, triethylene glycol is us

POLYMORPH FORMS OF ICOTINIB MALEATE AND USES THEREOF

Provided are Icotinib maleate(the compound of Formula I) and polymorph forms thereof, and methods of preparing and using them.